Respiratory Viral Infections-Focused Revelation Biosciences Turns To SPAC Deal
- Revelation Biosciences Inc is joining Petra Acquisition Inc (NASDAQ: PAIC) to create a NASDAQ-listed company with an enterprise value of $128 million.
- The merger is expected to close in Q4 2021, and the combined company will be listed on NASDAQ under the ticker symbol REVB.
- Revelation will pocket $73 million through the merger and use the money to advance REVTx-99, a nasal drop formulation designed to stimulate the innate immune system via TLR4-TRIF pathway agonism.
- In a 48-subject phase 1 trial, Revelation linked REVTx-99 to increased intranasal levels of the cytokine IP-10.
- Revelation identified IP-10 as the key cytokine of interest because it is upregulated in response to respiratory viral infection and linked to clinical efficacy in challenge studies.
- With phase 1 proof-of-principle data in hand, Revelation is now gearing up for further development.
- A 60-subject phase 2 influenza viral challenge study is slated to start in Q1 of 2022.
- REVTx-99 is also in development to treat chronic nasal congestion, with a phase 1 trial set to start this year.
- The same platform has generated a second, earlier-stage candidate, REVTx-200. Revelation sees the follow-up prospect as a way to improve the immune response to intramuscular vaccines.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.